Aldeyra Therapeutics (ALDX) Profit After Tax (2013 - 2026)
Aldeyra Therapeutics (ALDX) posted Profit After Tax of -$3.5 million for Q1 2026, up 46.57% on a QoQ basis from -$6.5 million in Q4 2025, and up 65.23% year-over-year from -$2.1 million in Q1 2025.
Aldeyra Therapeutics (ALDX) Profit After Tax (2013 - 2026) Analysis & Trends
Aldeyra Therapeutics' Profit After Tax history runs 14 years deep, the most recent figure standing at -$3.5 million for Q1 2026.
- Quarterly Profit After Tax rose 65.23% year-over-year to -$3.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$27.4 million (up 52.6% YoY) and the FY2025 annual result came in at -$33.8 million, up 39.45% from the prior year.
- Profit After Tax was -$3.5 million for Q1 2026 at Aldeyra Therapeutics, up from -$6.5 million in the prior quarter.
- Across five years, Profit After Tax topped out at -$3.5 million in Q1 2026 and bottomed at -$17.8 million in Q2 2022.
- A 5-year average of -$11.3 million and a median of -$9.9 million in 2025 frame the typical range for Profit After Tax.
- Annual changes were most pronounced in 2024 — Profit After Tax slumped 233.63% — and 2026, when it surged 65.23%.
- Aldeyra Therapeutics' Profit After Tax stood at -$12.9 million in 2022, then surged by 63.09% to -$4.8 million in 2023, then slumped by 233.63% to -$15.9 million in 2024, then soared by 59.25% to -$6.5 million in 2025, then surged by 46.57% to -$3.5 million in 2026.
- Business Quant data shows ALDX's Profit After Tax at -$3.5 million in Q1 2026, -$6.5 million in Q4 2025, and -$7.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,192.35 Bn | 67,192.06 Bn | - | -36.84 Mn |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.52 Bn | 466.73 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.73 Bn | 114.48 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.88 Bn | 61.13 Bn | 3.31 Bn | -65.60 Mn |
| 7 | Belite Bio | 63.11 Bn | 63.11 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 55.88 Bn | 50.70 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.48 Bn | 37.48 Bn | - | -453.82 Mn |
| 10 | Aldeyra Therapeutics | 95.30 Mn | 95.30 Mn | - | -3.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.45 Mn |
| Dec 31, 2025 | -6.46 Mn |
| Sep 30, 2025 | -7.69 Mn |
| Jun 30, 2025 | -9.77 Mn |
| Mar 31, 2025 | -9.93 Mn |
| Dec 31, 2024 | -15.86 Mn |
| Sep 30, 2024 | -15.11 Mn |
| Jun 30, 2024 | -16.85 Mn |
| Mar 31, 2024 | -8.08 Mn |
| Dec 31, 2023 | -4.75 Mn |
| Sep 30, 2023 | -8.19 Mn |
| Jun 30, 2023 | -8.99 Mn |
| Mar 31, 2023 | -15.62 Mn |
| Dec 31, 2022 | -12.88 Mn |
| Sep 30, 2022 | -14.55 Mn |
| Jun 30, 2022 | -17.78 Mn |
| Mar 31, 2022 | -16.79 Mn |
| Dec 31, 2021 | -15.75 Mn |
| Sep 30, 2021 | -15.79 Mn |
| Jun 30, 2021 | -14.94 Mn |